IBOV 167,567.45 ▼ 1.32% IPC MEX 70,388.96 ▼ 1.15% MERVAL 2,848,945 — — USD/BRL5.85▲ 1.28% USD/MXN18.77▲ 1.88% USD/CLP1,007▲ 1.38% USD/COP3,351▲ 1.01% USD/PEN3.41▲ 0.05% USD/ARS1,559▲ 0.43% USD/UYU40.61▲ 3.30% USD/PYG6,212▲ 3.32% USD/BOB11.64▲ 3.07% USD/DOP60.00▼ 0.50% USD/CRC441.73▲ 2.50% USD/GTQ7.64▲ 3.28% USD/HNL26.89▼ 0.10% USD/NIO36.62▲ 0.34% USD/VES913.46▼ 0.22% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.39▲ 2.57% USD/TTD6.70▲ 1.98% EUR/BRL6.42▲ 1.07% BRENT 89.21 ▼ 4.22% WTI 82.94 ▼ 3.57% IRON ORE 161.91 — — COPPER 5.66 ▼ 5.29% GOLD 3,758 ▼ 2.75% SILVER 44.96 ▼ 4.93% SOY 1,218 ▼ 0.61% CORN 441.25 ▼ 1.23% WHEAT 593.75 ▼ 0.25% COFFEE 273.55 ▼ 4.55% SUGAR 18.17 — 0.00% ORANGE JUICE 129.40 ▼ 4.15% COTTON 80.95 ▲ 4.69% COCOA 5,002 ▼ 0.56% BEEF 218.75 ▼ 0.01% CATTLE 336.30 ▲ 0.22% LITHIUM 55.54 ▼ 1.57% PETR4 42.82 ▼ 2.64% VALE3 59.24 ▼ 1.82% ITUB4 40.47 ▼ 1.03% BBDC4 14.30 ▼ 0.76% ABEV3 16.10 ▲ 1.07% BBAS3 14.20 ▼ 2.87% B3SA3 14.16 ▼ 3.34% WEGE3 51.56 ▲ 0.80% PRIO3 62.13 ▼ 2.86% SUZB3 55.73 ▲ 0.61% RENT3 29.85 ▲ 0.64% AZZA3 16.13 ▲ 3.13% CSAN3 3.12 ▼ 4.00% RAIZ4 18.49 ▼ 3.24% PCAR3 3.05 ▲ 5.54% GMAT3 4.09 ▼ 2.15% PSSA3 44.80 ▼ 2.44% CVCB3 0.77 ▼ 1.28% POSI3 3.24 ▲ 3.51% SLCE3 17.87 ▼ 1.05% NATU3 4.76 ▲ 0.21% BRKM5 2.63 ▼ 4.36% RANI3 8.10 ▼ 1.46% CSNA3 3.75 ▼ 0.53% IBOV 167,567.45 ▼ 1.32% IPC MEX 70,388.96 ▼ 1.15% MERVAL 2,848,945 — — USD/BRL 5.84 ▲ 0.99% USD/MXN 18.73 ▲ 1.70% USD/CLP 1,005 ▲ 1.26% USD/COP 3,351 ▲ 1.02% USD/PEN 3.41 ▲ 0.05% USD/ARS 1,559 ▲ 0.43% USD/UYU 40.61 ▲ 3.30% USD/PYG 6,212 ▲ 3.32% USD/BOB 11.64 ▲ 3.07% USD/DOP 60.00 ▼ 0.50% USD/CRC 441.73 ▲ 2.50% USD/GTQ 7.64 ▲ 3.28% USD/HNL 26.89 ▼ 0.10% USD/NIO 36.62 ▲ 0.34% USD/VES 913.46 ▼ 0.22% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.39 ▲ 2.57% USD/TTD 6.70 ▲ 1.98% EUR/BRL 6.41 ▲ 0.89% BRENT 89.21 ▼ 4.22% WTI 82.94 ▼ 3.57% IRON ORE 161.91 — — COPPER 5.66 ▼ 5.29% GOLD 3,758 ▼ 2.75% SILVER 44.96 ▼ 4.93% SOY 1,218 ▼ 0.61% CORN 441.25 ▼ 1.23% WHEAT 593.75 ▼ 0.25% COFFEE 273.55 ▼ 4.55% SUGAR 18.17 — 0.00% ORANGE JUICE 129.40 ▼ 4.15% COTTON 80.95 ▲ 4.69% COCOA 5,002 ▼ 0.56% BEEF 218.75 ▼ 0.01% CATTLE 336.30 ▲ 0.22% LITHIUM 55.54 ▼ 1.57% PETR4 42.82 ▼ 2.64% VALE3 59.24 ▼ 1.82% ITUB4 40.47 ▼ 1.03% BBDC4 14.30 ▼ 0.76% ABEV3 16.10 ▲ 1.07% BBAS3 14.20 ▼ 2.87% B3SA3 14.16 ▼ 3.34% WEGE3 51.56 ▲ 0.80% PRIO3 62.13 ▼ 2.86% SUZB3 55.73 ▲ 0.61% RENT3 29.85 ▲ 0.64% AZZA3 16.13 ▲ 3.13% CSAN3 3.12 ▼ 4.00% RAIZ4 18.49 ▼ 3.24% PCAR3 3.05 ▲ 5.54% GMAT3 4.09 ▼ 2.15% PSSA3 44.80 ▼ 2.44% CVCB3 0.77 ▼ 1.28% POSI3 3.24 ▲ 3.51% SLCE3 17.87 ▼ 1.05% NATU3 4.76 ▲ 0.21% BRKM5 2.63 ▼ 4.36% RANI3 8.10 ▼ 1.46% CSNA3 3.75 ▼ 0.53%
since 2009
Wednesday, November 18, 2026

Africa Ghana

Ghana’s Mahama Urges Africa to Make Its Own Medicines

By · · 5 min read
Pharmacy Oxford Street Accra Ghana
A pharmacy on Oxford Street in Accra, where most medicines are available over the counter or on prescription (Photo: Matti Blume, CC BY-SA 4.0 via Wikimedia Commons)

Key Facts

  • What happened President John Dramani Mahama called on African governments, banks and institutional investors to finance local pharmaceutical manufacturing at the Alamein Africa Forum in Egypt on 3 October 2026.
  • The scale Africa imports more than 70% of its pharmaceuticals and nearly 99% of its vaccines, leaving the continent exposed to global supply shocks.
  • The market The African Continental Free Trade Area could create a unified market of about 1.4 billion consumers for pharmaceutical manufacturers.
  • The proof An Africa CDC pooled tender for maternal and child-health products cut prices by 30–90%, with African manufacturers winning 50% of product lines.
  • Ghana’s role Ghana is positioning itself as a West African pharmaceutical manufacturing hub.
  • What comes next Delivery depends on reliable procurement, regulation through the African Medicines Agency, infrastructure and credible co-investment financing.

President John Dramani Mahama is urging African governments and investors to back local pharmaceutical manufacturing, framing import dependence as both a health-security risk and an industrial opportunity for a continental market of 1.4 billion consumers.

Free daily brief — no card needed
Get every Africa story in one morning email
We build you a personalized brief around the topics you follow — free for 7 days. Love it? Your first month after that is US$1.

President John Dramani Mahama has called on African governments, banks and institutional investors to finance local pharmaceutical manufacturing, arguing that the continent’s heavy reliance on imported medicines is a strategic vulnerability. Speaking at the Alamein Africa Forum in Egypt on 3 October 2026, he said Africa imports more than 70% of its pharmaceuticals and nearly 99% of its vaccines.

The investment case for local pharmaceutical manufacturing

Mahama’s pitch rests on the scale of the African Continental Free Trade Area, or AfCFTA. The trade bloc could create a unified market of about 1.4 billion consumers, allowing manufacturers to move beyond small national markets and build regional supply chains.

That scale, he argued, would help African countries retain foreign exchange currently spent on imports. It would also create higher-value jobs in research, production and distribution rather than relying on overseas suppliers.

The commercial logic is already visible in procurement. Mahama cited an Africa CDC pooled tender for maternal and child-health products that cut prices by 30–90%, while African manufacturers won 50% of product lines.

Accra, Ghana
File photo: Accra, Ghana

Beyond packaging to active ingredients and biologics

The strategic issue is power as well as public health. The COVID-19 pandemic exposed Africa’s dependence on overseas vaccine supply, leaving countries at the back of the queue during a global emergency.

Mahama is calling for production to progress beyond packaging and fill-and-finish operations. He wants African manufacturers to move into active pharmaceutical ingredients, biotechnology, research and biologics.

That shift would reduce vulnerability to global trade disruptions. It would also build industrial capabilities that extend far beyond the health sector, creating a foundation for broader scientific and manufacturing growth.

Ghana positions itself as a West African hub

Ghana is already positioning itself as a regional manufacturing centre. Mahama used the forum to promote local drug and vaccine production.

He also called for investment in generics, essential medicines, diagnostics and medical devices.

The message is consistent: Ghana wants external capital and technology, but on a co-investment basis rather than permanent dependency. That framing matters for how international pharmaceutical companies approach the market.

The geopolitical and commercial stakes

The push for local pharmaceutical manufacturing fits a broader pattern of African governments seeking to convert demographic scale into industrial leverage. The AfCFTA is central to that ambition, offering a single market that could make African production commercially viable for the first time.

This is part of the wider contest for influence and economic opportunity covered in Africa: The New Scramble. External partners from Europe, China, India and the Gulf states are all courting African health markets.

Mahama’s argument is that Africa should not simply be a buyer. It should be a producer, using its own demand to anchor industrial capacity and negotiate better terms with global suppliers.

What must happen for the plan to work

The commercial opportunity is substantial, but delivery depends on several conditions. Reliable procurement is essential, so that manufacturers can plan production without fearing sudden contract cancellations.

Regulation through the African Medicines Agency will also be critical. A credible continental regulator can build trust in African-made products and reduce the fragmentation that has long held back regional trade.

Infrastructure and politically credible financing round out the list. Mahama’s call to banks and institutional investors is an acknowledgement that public budgets alone cannot fund the shift to local production.

What to watch next

The next test will be whether African governments and development finance institutions translate Mahama’s call into concrete co-investment deals. The Africa CDC tender shows that pooled procurement can work, but scaling that model across the continent remains a challenge.

Ghana’s progress on local drug and vaccine production will be an early indicator of whether the country can attract the technology and capital it needs. Progress on active pharmaceutical ingredients, rather than just packaging, will be the clearest sign that the strategy is moving beyond rhetoric.

Frequently Asked Questions

How much of Africa’s pharmaceuticals are imported?

Africa imports more than 70% of its pharmaceuticals and nearly 99% of its vaccines, according to President John Dramani Mahama.

What is the AfCFTA and why does it matter for pharmaceuticals?

The African Continental Free Trade Area is a trade bloc that could create a unified market of about 1.4 billion consumers, making regional pharmaceutical manufacturing commercially viable.

What is Ghana doing to boost local drug production?

Mahama used the forum to promote local production of medicines and vaccines in Ghana.

RT
Ask Rio Times
Latin American markets, currencies and companies.
Open the full Ask Rio Times →

Connected Coverage

Sources

This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error

LatAm Markets: Live Signals → — real-time movers, turnover leaders and FX across Latin America.

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.